November 2, 2012 — Mevion Medical Systems announced the delivery of its fifth TriNiobium Core proton accelerator, the powerful proton source that is at the center of the revolutionary Mevion S250 Proton Therapy System. This accelerator will be delivered early next year to First Coast Oncology in Jacksonville, Fla. All 2013 and early 2014 Mevion S250 deliveries are already in the manufacturing stage.
“The Mevion S250 has redefined the economics, availability, and the future direction of proton therapy, by bringing the management and operation of proton therapy to the level of modern radiation therapy,” said Scot Ackerman, medical director for First Coast Oncology. “Our Mission has been to provide the most advanced radiation treatment for our cancer patients, and the Mevion S250 will allow us to offer to our patients the full benefits of proton therapy.”
The Mevion S250 proton therapy system represents the latest innovation in proton therapy, providing the same precise, non-invasive treatment advantages and capabilities of larger proton therapy systems but with a significantly reduced footprint, improved reliability, high patient throughput, more advanced clinical systems and lower implementation and operational costs. Powered by a patented gantry-mounted TriNiobium Core accelerator, the Mevion S250 has a footprint only slightly larger than a conventional linear accelerator.
In addition to the construction at First Coast Oncology, the Mevion S250 is installed at Washington University, St. Louis, Mo., and is under installation at Robert Wood Johnson University Hospital, New Brunswick, N.J. and Oklahoma University. An additional site in Florida, MD Anderson Cancer Center in Orlando just broke ground in September 2012.
More than a dozen Mevion S250 proton therapy systems are slated to be installed in the United States including five NCI Designated Comprehensive Cancer Center, and six international projects. “The simple and modular design of the Mevion S250 supports a lean and fast manufacturing process. This is a first in proton therapy which traditionally has been limited by the enormous size and complexity of the device”, says Joseph K. Jachinowski, chief executive officer of Mevion Medical Systems. The Mevion S250 is the only proton therapy system designed and manufactured in the United States, and has recently received United States Food and Drug Administration (FDA) 510(k) clearance and CE certification enabling Mevion customers to treat patients.
For more information: www.Mevion.com
February 02, 2024 
